A to Z / Cognitive

Noopept

Also known as N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, GVS-111.

Best known for The widely used Russian nootropic, a dipeptide derivative

Evidence★★☆☆☆

Safety dataPoorly characterised

Route Oral · sublingual

United StatesNot approved; not a lawful dietary supplement ingredient

AustraliaSchedule 4

as at 16 September 2026

What it is

Noopept is a dipeptide derivative: structurally related to the racetam nootropics but built on a two-amino-acid backbone. It was developed in Russia, where it is a registered medicine for cognitive impairment. It is not approved in most Western markets, and it is one of the most widely used nootropics in the world.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Semax, Selank, Cerebrolysin, Dihexa

Related entries

SemaxThe leading nootropic peptide · Evidence ★★☆☆☆
SelankAnxiety relief without sedation · Evidence ★★☆☆☆
CerebrolysinThe brain peptide mixture used clinically outside the West · Evidence ★★★☆☆
DihexaThe Alzheimer's research peptide at an early stage of study · Evidence ★☆☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Noopept. It is not medical advice and not a recommendation to use it.